Ultra-conservative Fertility-sparing Strategy for Bilateral Borderline Ovarian Tumours: an 11-year Follow-up
Overview
Authors
Affiliations
Background: This is a prospective long-term extension study of a randomized controlled trial aimed to assess the risk-benefit ratio of an ultra-conservative fertility-sparing approach in patients with bilateral borderline ovarian tumours (BOTs).
Methods: The experimental group (n = 15) was treated with an ultra-conservative surgical approach consisting of bilateral cystectomy, whereas the control group (n = 17) received a less conservative surgery consisting of oophorectomy plus controlateral cystectomy alone. All patients received a complete laparoscopic staging followed by a fertility enhancement programme. Patients who completed childbearing were treated with a non-conservative standard treatment at the first recurrence.
Results: After a follow-up period of 128 (9 interquartile range (IQR); 115-150 range) and 132 (7 IQR; 117-152 range) months for the experimental and control groups, respectively (P = 0.25), the time to first baby-in-arm (P < 0.02) and the relative rate (RR) of baby-in-arm (8.05 [95% confidence interval (CI), 1.20-9.66; P < 0.01]) were significantly lower and higher, respectively, for the experimental compared with the control group. Although the time to first recurrence was significently (P < 0.01) shorter for the experimental group, in the regression analysis the difference did not reach the statistic significance (P = 0.14), and the RR of recurrence (1.23 [95% CI, 0.62-3.17; P = 0.41]) was not significant. Finally the number needed to treat for pregnancy was three, the number needed to harm for radical surgery was only two.
Conclusions: The ultra-conservative fertility-sparing approach is more effective than the standard approach in terms of reproductive outcomes, but presents a higher oncological risk.
Tortajada Valle M, Agusti N, Fuste P, Mension E, Diaz-Feijoo B, Glickman A J Clin Med. 2024; 13(18).
PMID: 39336945 PMC: 11432542. DOI: 10.3390/jcm13185458.
Cang W, Liang C, Wang D, Xue X, Cao D, Yang J J Clin Med. 2023; 12(18).
PMID: 37762767 PMC: 10531562. DOI: 10.3390/jcm12185827.
Anggraeni T, Tjokroprawiro B J Gynecol Oncol. 2022; 34(1):e26.
PMID: 36562132 PMC: 9807355. DOI: 10.3802/jgo.2023.34.e26.
Garofalo G, Bucella D, Thomas D, Buxant F Clin Case Rep. 2022; 10(12):e6609.
PMID: 36483854 PMC: 9723236. DOI: 10.1002/ccr3.6609.
The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age.
Della Corte L, Mercorio A, Serafino P, Viciglione F, Palumbo M, De Angelis M Front Surg. 2022; 9:973034.
PMID: 36081590 PMC: 9445208. DOI: 10.3389/fsurg.2022.973034.